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ABSTRACT
Objective To completely and quanti#ably determine 
the effect of systemic lupus erythematosus (SLE) on 
pregnancy outcomes in a Chinese cohort.
Design A retrospective cohort study.
Setting Data were collected at a tertiary medical centre 
located in Shanghai, China, from September 2011 to May 
2017.
Participants We assigned 338 pregnant women with SLE 
to the study cohort and 1014 randomly selected pregnant 
women without SLE (three for every woman with SLE) to 
a comparison cohort. The relevant medical records of all 
pregnant women were retrospectively reviewed. Cases 
of multiple pregnancy and cases in which an arti#cial 
abortion was performed for personal reasons were 
excluded.
Primary and secondary outcome measures Maternal 
and fetal outcomes were primary outcomes, and 
management of antenatal care was the secondary 
outcome.
Results The risks of pregnancy-induced hypertension 
(OR 2.68, 95% CI 1.75 to 4.09), pre-eclampsia (OR 
3.13, 95% CI 1.95 to 5.03) and premature rupture 
of membranes (OR 2.53, 95% CI 1.46 to 4.40) were 
signi#cantly different between women with and without 
SLE. Gestational diabetes was negatively associated with 
SLE in pregnant women (OR 0.49, 95% CI 0.28 to 0.85). 
Pregnant women with SLE displayed signi#cantly higher 
rates of fetal loss (OR 10.23, 95% CI 5.08 to 20.59), 
including spontaneous abortion (OR 4.42, 95% CI 1.52 to 
12.80), therapeutic abortion (OR 16.57, 95% CI 5.80 to 
47.35) and stillbirth (OR 13.25, 95% CI 1.49 to 118.11), 
and a higher risk of preterm birth (OR 3.15, 95% CI 2.21 
to 4.50), intrauterine growth restriction (OR 2.20, 95% CI 
1.35 to 3.58), a child who was small for the gestational 
age (OR 1.86, 95% CI 1.11 to 3.13), a caesarean section 
(OR 4.73, 95% CI 3.30 to 6.80) or a neonatal intensive 
care unit admission (OR 3.48, 95% CI 2.21 to 5.48) than 
women in the non-SLE population after adjusting for 
confounding factors.
Conclusions In this study, SLE signi#cantly increased 
the risk of adverse pregnancy outcomes. Therefore, a 
preconception assessment and close antenatal monitoring 
by both rheumatologists and obstetricians should be 
performed in pregnant women with SLE.
INTRODUCTION 
Systemic lupus erythematosus (SLE) is an 
autoimmune disease that involves multiple 
organs and most commonly occurs in young 
women, in whom it has an incidence of 
0.3-31.5/100 000 person-years and preva-
lence of 3.2-517.5/100 000.1 2 Women with 
SLE have a normal fertility rate,2 and preg-
nancy is therefore a frequent subject of 
interest for these patients. As treatments for 
pregnant women with SLE have improved 
and increasingly involve multidisciplinary 
management, pregnancy outcomes have 
dramatically improved in recent decades.3 
Although several studies have compared preg-
nancy outcomes between women with SLE 
and the general population4–7 and reported 
that SLE is associated with adverse obstetric 
outcomes, few studies have examined these 
outcomes in a Chinese cohort. Therefore, we 
have compared maternal and fetal outcomes 
between women with SLE and women in the 
Strengths and limitations of this study
 ? This study represents the #rst comparison of ma-
ternal and fetal outcomes between pregnant wom-
en with and without systemic lupus erythematosus  
(SLE) in a Chinese cohort.
 ? Additionally, the present study included large sam-
ples of both patients with SLE and controls com-
prising a total of 1350 individuals, and no data were 
missing for any of these patients.
 ? Furthermore, the maternal and fetal outcomes eval-
uated in this study were comprehensive and re&ect 
almost every key aspect of pregnancy.
 ? One limitation of this retrospective study was inher-
ent biases, including selection bias and information 
bias.
 ? The second limitation was the lack of some details 
regarding baseline population characteristics, for 
example, education, body mass index and family in-
come, in the clinical records for some of the included 
participants.
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general population to completely and quantifiably clarify 
the effect of SLE on pregnancy outcomes in a Chinese 
cohort.
MATERIALS AND METHODS
Study sample
This retrospective cohort study was performed in a single 
centre. Our study cohort consisted of pregnant patients 
with SLE who were treated in Ren Ji Hospital, Shanghai 
Jiao Tong University School of Medicine between 
September 2011 and May 2017. Multiple gestations and 
elective terminations for personal reasons were excluded. 
SLE was diagnosed according to the revised criteria for the 
classification of SLE developed by the American College 
of Rheumatology.8 All participants with SLE were evalu-
ated by an experienced gynaecologist at least monthly 
and by a rheumatologist at least once per trimester. At 
each evaluation, a physical examination and laboratory 
tests were performed, and medications were adjusted as 
needed.
Our comparison cohort was randomly selected from 
women with singleton pregnancies who were not diag-
nosed with SLE and attended the same hospital. Control 
participants were matched with the study group by delivery 
time (three controls were selected for every woman with 
SLE) and received regular, routine antenatal care.
Variables of interest
Medical records from both cases and controls were 
retrospectively reviewed, and pregnancy outcomes were 
systematically evaluated.
Population characteristics
The baseline characteristics of the population were 
recorded to identify potential confounding factors. These 
factors included maternal age at delivery, region, nulli-
parity, history of spontaneous abortion and comorbidities. 
Region was categorised as city and rural areas. A history 
of spontaneous abortion was categorised as 0, 1 and ≥2, 
according to the numbers of miscarriages. Comorbidi-
ties included a prepregnancy diagnosis of hypertension 
or diabetes. None of the women in the study population 
had ever smoked or used alcohol during pregnancy; 
therefore, these two variables were not included in the 
study. For the SLE cohort, the history of SLE, pregesta-
tional SLE status, SLE clinical manifestations (including 
nephritis, mucocutaneous, haematological disorder, 
neurological disorder, arthritis, serositis and antiphospho-
lipid syndrome (APS)), the laboratory test data and medi-
cations were also extracted. Laboratory data included 
a complete blood count, urinalysis and levels of serum 
albumin, 24-hour urinary protein, complement 3 (C
3
), 
complement 4 (C
4
), antinuclear antibodies, anti-double 
standard DNA antibodies (anti-dsDNA), anti-Smith anti-
bodies (anti-Sm), anti-SSA/Ro antibodies, anti-SSB/La 
antibodies and antiphospholipid (aPL) antibodies, which 
included anticardiolipin antibodies, anti-β2-glycoprotein 
I antibodies and lupus anticoagulant. APS was defined 
according to the Sapporo criteria.9 All laboratory tests 
were performed using standardised methods.
The pregestational clinical status of patients with SLE 
was categorised into the remission stage, which was 
defined as a patient who took a low dose of or stopped 
prednisone treatment without clinical manifestations of 
SLE activity for more than 6 months prior to concep-
tion. The active stage was defined as patients presenting 
clinical manifestations of SLE activity, including central 
nervous system and renal involvement, vasculitis, arthritis, 
myositis, fever, rash, pleurisy, pericarditis and hypocom-
plementaemia. The initial onset during pregnancy was 
defined as a new onset of SLE during pregnancy.
Maternal outcomes
All outcome variables were dichotomous. The abstracted 
maternal outcomes and definitions are listed below.
 ? Pregnancy-induced hypertension (PIH): a de novo 
increase in blood pressure to ≥140/90 mm Hg on at 
least two occasions ≥6 hours apart observed after the 
20th week of pregnancy.
 ? Pre-eclampsia: PIH with proteinuria >0.3 g/L/day in 
the absence of a urinary tract infection or the abrupt 
onset of hypertension and proteinuria after 20 weeks 
of gestation. Seizures were required for a diagnosis of 
eclampsia.
 ? HELLP (haemolysis, elevated liver enzymes and low 
platelet count) syndrome: the presence of haemol-
ysis, high levels of lactate dehydrogenase or total 
bilirubin >12 mg/L, alanine aminotransferase levels 
more than twofold the upper normal value and 
thrombocytopenia <100×109 cells/L.
 ? Gestational diabetes mellitus (GDM) was defined as 
any degree of glucose intolerance with onset or first 
recognition during pregnancy.10
 ? Premature rupture of membranes (PROM): a rupture 
of the amniotic sac prior to the onset of labour. We 
further divided this condition into term PROM and 
preterm PROM (PPROM), according to the neonatal 
gestational age.
 ? Postpartum haemorrhage (PPH) was defined as blood 
loss of 500 mL or more within 24 hours after birth.11
 ? Peripartum infection was defined as an infection of 
the genital tract occurring at any time between the 
onset of membrane rupture or labour and the 42nd 
postpartum day.12
 ? Maternal death: the death of a woman during preg-
nancy or within 42 days of the termination of a 
pregnancy, regardless of the duration or site of the 
pregnancy, of any cause related to or aggravated by 
the pregnancy or its management, but not any acci-
dental or incidental causes.13
 ? An SLE flare was defined as a measurable increase 
in disease activity in one or more organ systems 
involving new or worsening clinical signs and symp-
toms and/or laboratory measurements that met the 
SLE diagnostic criteria ACR1997.8 The flare must 
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be considered clinically significant by the assessor 
and a change or an increase in treatment is typically 
considered.14
Fetal outcomes
All outcome variables were dichotomous and continuous. 
The abstracted fetal outcomes and definitions are listed 
below.
 ? Live birth: the birth of a living child.
 ? Fetal loss: defined as all pregnancies that did not end 
with a live birth,15 including spontaneous abortions, 
therapeutic abortions, stillbirths or intrauterine fetal 
deaths. Additional definitions were:
 – Spontaneous abortion: spontaneous termination 
of a pregnancy prior to 28 weeks of gestation.16 We 
further divided spontaneous abortions into <10 
weeks and ≥10 weeks.
 – Therapeutic abortion: abortion for therapeutic 
reasons because the pregnancy might be a threat 
to maternal health, such as a life-threatening SLE 
flare or other severe obstetric complications, in-
cluding severe thrombocytopenia or HELLP syn-
drome, etc or fetal lethal malformations, including 
the maldevelopment of cardiac anatomy.
 – Stillbirth or intrauterine fetal death: any baby born 
without signs of life at ≥28 completed weeks of 
gestation.17
 ? Intrauterine growth restriction (IUGR): factors that 
limit the potential for the intrauterine growth of the 
fetus.18
 ? Small for gestational age (SGA): infants whose weight 
was lower than the lower 10% limit of the CI of the 
normal curve for gestational weight.19
 ? Neonatal death: live birth who died during the first 28 
completed days of life.20
 ? Preterm birth: was defined as delivery <37 weeks 
of gestation. We further divided this condition 
into very preterm (28–32 weeks) and moderate 
to late preterm (≥32 weeks), according to WHO 
definitions.21
 ? Method of childbirth: caesarean section or vaginal 
birth. We further divided caesarean section into elec-
tive and emergency caesarean section, according to 
the indications for caesarean section.22
 ? Congenital malformation: all types of congenital 
malformation.
 ? Neonatal gender: male and female.
 ? Neonatal intensive care unit (NICU): neonates 
who required intensive medical attention and were 
admitted into a special area of the hospital called the 
NICU.
 ? 1 min and 5 min Apgar scores: an Apgar score >7 was 
defined as normal, whereas a score <7 was considered 
to indicate moderate or severe hypoxia.23
 ? Birth weight: neonatal birth weight is presented in 
grams.
 ? Gestational days: neonatal gestational days is 
presented in days.
Statistical analysis
Descriptive data are presented as means±SD or as frequen-
cies. Categorical variables were analysed using the χ2 test 
or Fisher’s exact probability test, as appropriate. Contin-
uous variables were analysed using Student’s t-test.
The denominator used in the analyses of all maternal 
outcomes, stillbirths and live births was all reported preg-
nancies. For all other fetal outcomes (excluding stillbirths 
and live births), the denominator was all live births.
Logistic regression analyses were performed to 
compute crude ORs with 95% CIs for maternal and fetal 
outcomes. Logistic regression models were adjusted for 
potential confounding factors, including maternal age, 
region, nulliparity, a history of spontaneous abortion 
and comorbidities. These analyses yielded new adjusted 
ORs with 95% CIs. All tests were two tailed, and p<0.05 
was considered statistically significant. All analyses were 
performed using SPSS V.22.0.
This study used a retrospective, observational design, 
the Medical Ethical Committee granted a waiver for 
informed consent for this study. Approval to obtain clin-
ical data from the database was received from the Office 
of the Medical Director of the hospital. All patient infor-
mation remained confidential.
RESULTS
Population characteristics
Three hundred and thirty-eight pregnant women with 
SLE (cases) and 1014 pregnant without SLE (controls) 
who were monitored between September 2011 and May 
2017 were included. The distributions of the baseline 
characteristics of the population are shown in table 1. 
Mean ages were not significantly different between the 
two cohorts. Women with SLE were more likely to reside 
in a city than the controls, and most of the pregnancies 
in women with SLE were nulliparous. A history of spon-
taneous abortion, particularly ≥2 abortions, was more 
common in women with SLE. Significant differences in 
comorbid conditions were not observed between the 
women with SLE and the controls. The proportion of 
women in whom diabetes and/or hypertension was diag-
nosed prior to pregnancy was not significantly different 
between the SLE and non-SLE populations. Data for 
some variables, such as laboratory test data and SLE clin-
ical manifestations, were not available for the non-SLE 
group because we do not perform these laboratory tests 
on patients without SLE manifestations. Regarding the 
SLE group, the mean duration of SLE was 5.6±4.3 years 
(range 0–20 years). Notably, 86.7% of pregnant women 
with SLE were in the remission stage, 1.8% were in the 
active age and 11.5% of women were first diagnosed with 
SLE during pregnancy.
The most common SLE clinical manifestations were 
mucocutaneous lesions, which were identified in 31.4% 
of patients, followed by lupus nephritis in 28.7%, arthritis 
in 20.7%, haematological disorders in 19.5%, serositis 
in 5.0% and neurological disorders in 1.5%. APS was 
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observed in 9.5% of the pregnant women with SLE. 
The mean 24-hour urinary protein level was 1.04±2.43 g 
(range, 0.01–16.7 g). Pregnant women were positive for 
autoantibodies at the following frequencies: anti-dsDNA 
in 261 patients (77.2%), anti-Ro/SSA in 150 patients 
(44.4%), anti-La/SSB in 47 patients (13.9%) and anti-Sm 
in 20 patients (5.9%). Forty-six patients were positive for 
aPL antibodies. C
3
 and C
4
 hypocomplementaemia was 
present in 90 (26.6%) and 60 patients (17.8%), respec-
tively (table 1).
Maternal outcomes
The rate of adverse maternal outcomes was several fold 
higher in women with SLE than in the non-SLE popula-
tion during pregnancy. PIH and pre-eclampsia/eclampsia 
were diagnosed in 19.2% and 14.2%, respectively, of the 
Table 1 Baseline clinical characteristics of pregnant women with and without SLE
Variables SLE cases (n=338) Non-SLE cases (n=1014) P values
Characteristics
Age (years, mean±SD) 29.5±4.0 29.7±4.3 0.59
History of spontaneous abortion (frequency)
  0 265 (78.4%) 903 (89.1%) 0.00**
  1 46 (13.6%) 64 (6.3%)
  ≥2 27 (8.0%) 47 (4.6%)
History of SLE (years, mean±SD, range) 5.6±4.3 (0–20) NA
Region
  City 237 (70.1%) 318 (31.4%) 0.00**
  Rural 101 (29.9%) 695 (68.6%)
Nulliparity 291 (86.1%) 706 (69.6%) 0.00**
Clinical comorbidities
Prepregnancy diabetes 1 (0.3%) 4 (0.4%) 1.00
Prepregnancy hypertension 10 (3.0%) 21 (2.1%) 0.35
Pregestational SLE status
Remission stage 293 (86.7%) NA
Active stage 6 (1.8%) NA
Initial onset 39 (11.5%) NA
SLE clinical manifestation
Nephritis 97 (28.7%) NA
Mucocutaneous 106 (31.4%) NA
Haematological disorder 66 (19.5%) NA
Neurological disorder 5 (1.5%) NA
Arthritis 70 (20.7%) NA
Serositis 17 (5.0%) NA
APS 32 (9.5%) NA
Laboratory test during pregnancy
24-Hour urinary protein level (g, mean±SD, range) 1.0±2.4 (0.0–16.7) NA
Anti-dsDNA 261 (77.2%) NA
Anti-Ro/SSA 150 (44.4%) NA
Anti-La/SSB 47 (13.9%) NA
Anti-Sm 20 (5.9%) NA
aPL 46 (13.6%) NA
Hypocomplementania-C3 90 (26.6%) NA
Hypocomplementania-C4 60 (17.8) NA
**P<0.01.
Anti-Sm, anti-Smith; Anti-dsDNA, anti-double stranded DNA; aPL, antiphospholipid; APS, antiphospholipid  syndrome; C3, complement 3; C4, 
complement 3; NA, not applicable.
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women with SLE. After adjusting for confounding factors, 
the risks of PIH (OR 2.68, 95% CI 1.75 to 4.09) or pre-ec-
lampsia (OR 3.13, 95% CI 1.95 to 5.03) remained high. 
The proportion of infection was low, and peripartum 
infections occurred in 0.9% (3/338) of the women 
with SLE and none of the control women. Interestingly, 
the rate of GDM was lower in women with SLE than in 
the controls, and the OR remained unchanged after 
adjusting for confounding factors (OR 0.49, 95% CI 0.28 
to 0.85). Although we did not observe a difference in 
PROM between the two groups, a significant difference in 
PPROM was observed, and the OR remained high, even 
after adjusting for confounding factors (OR 2.53, 95% CI 
1.46 to 4.40). Significant differences in other maternal 
outcomes, including PPH and HELLP syndrome, were 
not observed between the two groups. The SLE flare rate 
was 24.0% in the SLE group. Maternal deaths did not 
occur in either group (table 2).
Fetal outcomes
Women with SLE had a higher total fetal loss rate 
(OR 10.23, 95% CI 5.08 to 20.59) than the non-SLE popu-
lation after adjusting for confounding factors. Among the 
causes of fetal loss in women with SLE, 3.3% experienced 
a spontaneous abortion, whereas 6.2% underwent a ther-
apeutic abortion and 1.8% had a stillbirth. Furthermore, 
most of the spontaneous abortions occurred at ≥10 weeks, 
regardless of the group. After adjusting for confounding 
factors, the risks of a spontaneous abortion (OR 4.42, 
95% CI 1.52 to 12.80), therapeutic abortion (OR 16.57, 
95% CI 5.80 to 47.35) or a stillbirth (OR 13.25, 95% CI 
1.49 to 118.11) were still high.
Among women who achieved a live birth, the rates of 
preterm were 3.15-fold higher in the pregnant women 
with SLE than in the controls. Both the very preterm and 
moderate to late preterm subgroups had higher adjusted 
ORs of 3.57 (95% CI 1.65 to 7.72) and 2.76 (95% CI 1.90 
to 4.03), respectively. Caesarean births occurred at a 4.73-
fold higher rate in the SLE group, and 77% of patients 
with SLE tended to undergo an elective caesarean section. 
The rate of NICU admission for neonates was also higher 
in women with SLE. IUGR and SGA were observed in 
12.3% and 10.0% of pregnancies in women with SLE, 
respectively. The adjusted ORs were 2.20 and 1.86, respec-
tively, for each outcome (all p values<0.05). Further-
more, we also observed lower neonatal birth weights 
(2763.7±588.7 g) and gestational days (259.3±16.2 days) 
for pregnant women with SLE (both p<0.01). No neonatal 
deaths occurred in either group. Finally, significant differ-
ences in the rates of congenital malformations, neonatal 
genders or the proportions of low Apgar scores were not 
observed between the cohorts (table 3). Only two cases of 
neonatal lupus occurred in the women with SLE, both of 
which presented as mucocutaneous lesions.
Medications used during pregnancy by women with SLE
Medications were recorded for the SLE group and 
mainly included five kinds of medicines. Of the 338 
pregnant women with SLE, most (97.6%) were treated 
with glucocorticoids, with a mean dose of 7.5 mg/day 
(range 2.5–40 mg). Approximately, 75.4% and 74.6% of 
patients with SLE took hydroxychloroquine and low-dose 
aspirin (25–75 mg), respectively. Only a small proportion 
of patients (3.8%) took azathioprine, and 22.2% of the 
patients used low-molecular-weight-heparin (LMWH) 
during their pregnancy.
DISCUSSION
Principal #ndings
In this study, pregnant women with SLE have a higher 
risk of adverse maternal outcomes, such as PIH, pre-ec-
lampsia/eclampsia, PPROM and peripartum infection, 
than pregnant women without SLE. Furthermore, SLE 
Table 2 Maternal outcomes in patients with SLE and non-SLE
Maternal outcomes SLE (n=338) Non-SLE (n=1014) Crude OR (95% CI) Adjusted OR†(95% CI)
PIH (%) 65 (19.2%) 91 (9.0%) 2.42 (1.71 to 3.41)** 2.68 (1.75 to 4.09)**
Pre-eclampsia/eclampsia (%) 48 (14.2%) 59 (5.8%) 2.68 (1.81 to 4.10)** 3.13 (1.95 to 5.03)**
HELLP (%) 1 (0.3%) 2 (0.2%) 1.50 (0.14 to 16.11) 2.35 (0.18 to 31.60)
GDM (%) 19 (5.6%) 117 (11.5%) 0.46 (0.28 to 0.75)** 0.49 (0.28 to 0.85)*
PROM (%) 67 (19.8%) 157 (15.5%) 1.35 (0.98 to 1.85) 1.35 (0.95 to 1.92)
  TPROM (%) 38 (11.2%) 117 (11.5%) 0.97 (0.66 to 1.43) 0.94 (0.61 to 1.44)
  PPROM (%) 29 (8.5%) 40 (3.9%) 2.29 (1.39 to 3.75)** 2.53 (1.46 to 4.40)**
PPH (%) 8 (2.4%) 18 (1.8%) 1.34 (0.58 to 3.11) 1.39 (0.54 to 3.53)
SLE &are (%) 81 (24.0%) NA NA NA
*P<0.05.
**P<0.01.
†Adjusted ORs were calculated using a logistic regression analysis and were adjusted for maternal age, region, nulliparity, history of 
spontaneous abortion, history of diabetes and history of hypertension.
GDM, gestational diabetes; HELLP, haemolysis, elevated liver enzymes and low platelet count; NA, not  applicable; PPH, postpartum 
haemorrhage; PPROM, preterm premature rupture of membranes; PIH, pregnancy-induced hypertension; SLE, systemic lupus 
erythematosus; TPROM, term premature rupture of membranes. 
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was also associated with adverse fetal outcomes, including 
a high fetal loss risk, such as spontaneous abortion, partic-
ularly ≥10 weeks, therapeutic abortion and stillbirth; 
higher rates of preterm births, caesarean sections, mainly 
elective and NICU admissions; and a significantly higher 
number of infants with growth restriction (eg, IUGR or 
SGA). The elevated risk conferred by SLE on each of 
these factors indicates that preconception assessments 
and antenatal monitoring are both important in preg-
nant women with SLE.
Comparisons with previous studies
We observed differences in several baseline demographic 
features between the women with SLE and those without 
in our cohort. Women with SLE were more likely to 
reside in a city and to have a nulliparous pregnancy than 
women in the non-SLE group. Importantly, women with 
SLE more frequently experienced a spontaneous abor-
tion, which may potentially be associated with the high 
rate of adverse pregnancy outcomes observed in women 
with SLE.7 Differences in the prepregnancy incidences of 
chronic diseases were not observed between the women 
with and without SLE. This finding was also reported in 
two previous cohort studies.24 25
SLE is an important risk factor for fetal loss, including 
spontaneous abortion, therapeutic abortion and still-
birth. This finding was also reported in several previous 
cohort studies performed in other settings.4 7 24 26–30 In 
the present study, the rates of stillbirth and spontaneous 
abortion in the SLE group were 1.8% and 3.3%, respec-
tively. These rates are much lower than the rates reported 
in other studies. This finding might be due to the use 
of different terms to define outcomes. However, in the 
present study, a higher rate of therapeutic abortion was 
observed in the SLE group (6.2% in the SLE group vs 
0.5% in the non-SLE group). Few previous studies have 
reported this outcome.7 24 31 One systemic review reported 
the rate of elective abortion, but the OR was not signif-
icant (OR 1.19, 95% CI 0.76 to 1.88).30 However, their 
definition of elective abortion differed from the defini-
tion used in the present study. In our study, therapeutic 
abortion was defined as an abortion performed for a 
therapeutic reason, but not elective abortions based on 
Table 3 Fetal outcomes in patients with SLE and non-SLE
Fetal outcomes SLE (n=338) Non-SLE (n=1014) Crude OR (95% CI) Adjusted OR† (95% CI)
Fetal loss (%) 38 (11.2%) 13 (1.3%) 9.75 (5.13 to 18.55)** 10.23 (5.08 to 20.59)**
Spontaneous abortion (%) 11 (3.3%) 7 (0.7%) 4.84 (1.86 to 12.59)** 4.42 (1.52 to 12.80)**
  <10 weeks (%) 2 (0.6%) 0 (0.0%) NA NA
  ≥10 weeks (%) 9 (2.7%) 7 (0.7%) 3.94 (1.50 to 10.65)** 3.79 (1.25 to 11.44)*
Therapeutic abortion (%) 21 (6.2%) 5 (0.5%) 13.37 (5.00 to 35.74)** 16.57 (5.80 to 47.35)**
Stillbirth (%) 6 (1.8%) 1 (0.1%) 18.31 (2.20 to 152.62)** 13.25 (1.49 to 118.11)*
Live birth SLE (n=300) Non-SLE (n=1001)
IUGR (%) 37 (12.3%) 57 (5.7%) 2.33 (1.51 to 3.60)** 2.20 (1.35 to 3.58)**
SGA (%) 30 (10.0%) 53 (5.3%) 1.99 (1.25 to 3.17)** 1.86 (1.11 to 3.13)*
Preterm birth (%) 86 (28.7%) 133 (13.3%) 2.62 (1.92 to 3.58)** 3.15 (2.21 to 4.50)**
  Very preterm (%) 15 (5.0%) 19 (1.9%) 2.72 (1.37 to 5.42)** 3.57 (1.65 to 7.72)**
  Moderate to late preterm (%) 71 (23.7%) 114 (11.4%) 2.41 (1.73 to 3.36)** 2.76 (1.90 to 4.03)**
Caesarean section (%) 255 (85.0%) 557 (55.6%) 4.51 (3.21 to 6.35)** 4.73 (3.30 to 6.80)**
  Elective caesarean (%) 231 (77.0%) 298 (29.7%) 8.37 (5.32 to 13.15)** 9.27 (5.65 to 15.21)**
  Emergency caesarean (%) 24 (8.0%) 259 (25.8%) 0.12 (0.08 to 0.19)** 0.11 (0.07 to 0.18)**
Congenital malformation (%) 4 (1.3%) 10 (1.0%) 1.34 (0.42 to 4.30) 1.60 (0.43 to 5.97)
Neonatal gender (boys) (%) 149 (49.7%) 548 (54.7%) 0.82 (0.63 to 1.06) 0.84 (0.63 to 1.11)
NICU (%) 48 (16.0%) 66 (6.6%) 2.70 (1.81 to 4.01)** 3.48 (2.21 to 5.48)**
Apgar score at 1<7 (%) 3 (1.0%) 6 (0.6%) 1.68 (0.42 to 6.74) 2.47 (0.55 to 11.14)
Apgar score at 5<7 (%) 0 (0.0%) 2 (0.2%) NA NA
Birth weight (g)±SD 2763.7±588.7 3211.3±592.8 NA NA
Gestational days (d)±SD 259.3±16.2 269.7±15.3 NA NA
*P<0.05.
**P<0.01.
†Adjusted ORs were calculated using logistic regression analyses, which were adjusted for maternal age, region, nulliparity, history of 
spontaneous abortion, history of diabetes and history of hypertension.
IUGR, intrauterine growth restriction; NA, not applicable; NICU, neonatal intensive care unit; SGA, small for gestational age; SLE, systemic 
lupus erythematosus. 
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the mother’s will. This definition may have contributed 
to the low rates of spontaneous abortions and stillbirths 
observed in our study, because pregnancies were termi-
nated in some patients with severe cases of SLE using 
therapeutic abortion during an early trimester to main-
tain the health of the mother.
The results of our study confirm that PIH and pre-ec-
lampsia are significant problems during pregnancy in 
women with SLE. In our study, nearly one-fifth of preg-
nant women with SLE experienced the complications 
of significant hypertension and pre-eclampsia, whereas 
only 5.8%–9.0% of the pregnancies in healthy women 
were affected by these conditions. The ORs remained 
significant, even after adjusting for confounding factors. 
SLE flares and pre-eclampsia are important and diffi-
cult to recognise in pregnant patients with SLE because 
both conditions are associated with proteinuria, dete-
riorating renal function, hypertension and sometimes 
even coexist. Although several guidelines or biomarkers, 
such as placental growth factor and vascular endothelial 
growth factor are available, they display limited utility in 
practical clinical settings.3 In our study, we considered 
several clinical manifestations together, including the 
onset time of hypertension, complement levels, anti-
dsDNA levels, erythrocyte sedimentation rate, involve-
ment of other organs and even responses to steroids. 
This differential diagnosis was a comprehensive process, 
and it was always assessed by an experienced gynaecol-
ogist or a rheumatologist in our study. Uncontrolled 
hypertension has been shown to predict poor preg-
nancy outcomes,3 31 32 and guidelines recommend the 
implementation of measures to control blood pressure 
in these patients.3 33 In the present study, the rate of 
SLE flares was 24% and might have contributed to the 
adverse pregnancy outcomes, as reported previously.34 
However, as the main goal of this article was to compare 
pregnancy outcomes between women with and without 
SLE, we did not further explore the effects of flares on 
pregnancy outcomes among the SLE group, which could 
be a future study direction.
Although a few cases of peripartum infections were 
reported in each group, the SLE group had a slightly 
higher proportion of infections. Clowse et al6 and Nili et 
al
35 reported similar results. This effect may be related 
to the nature of the immune dysregulation observed in 
patients with SLE or may be associated with the immuno-
suppressive nature of treatments for SLE.
Interestingly, we noticed a significantly lower rate of 
GDM in women with SLE than in the controls (5.6% vs 
11.5%), even after adjusting for confounding factors. 
Only one previous study reported the same result. In the 
study by McGrory et al, none of the patients in the SLE 
group developed GDM, whereas 12% of patients in the 
non-SLE group developed GDM.31 Clowse et al reported 
a higher rate of pre-GDM in the SLE group, potentially 
because these patients were administered corticosteroids 
during pregnancy.6 Further studies of larger populations 
should be performed.
The rate of caesarean section surgeries was surprisingly 
high in our study (SLE vs non-SLE: 85% vs 55.6%), and 
it was far higher than the rates reported in most previous 
studies. A national US population-based study performed 
in 2000–2003 reported a 36.6% caesarean rate in patients 
with SLE.6 Two studies conducted in Northern Europe 
reported caesarean rates of 32%–39% in pregnant women 
with SLE and 16%–24% in non-SLE pregnant women.5 36 
However, Saavedra et al reported a high caesarean rate 
(77.1%–86.5%) in a Latin American SLE group, consis-
tent with our result. The main explanations were Mexican 
sociocultural, economic, medical-legal and biomedical 
factors.37 Although one study reported the opposite result 
(SLE vs non-SLE: 30% vs 53%), the authors recruited 
patients who had received a kidney transplant, which 
may have contributed to the difference in their results. 
Although the absolute rate was high in both groups in 
our study, SLE was still a risk factor for caesarean section. 
Furthermore, most patients with SLE tended to undergo 
an elective caesarean, mainly because doctors and patients 
tended to choose caesarean section to prevent complica-
tions related to SLE during delivery. The extremely high 
caesarean section rate observed in our study reflects the 
true clinical situation in China. In 2008, WHO suggested 
that nearly half of all births in China are delivered via 
caesarean section.38 Some of the potential reasons for 
this high rate include a fear of pain and accidents during 
vaginal birth, an uneasy doctor–patient relationship, the 
profitability of caesarean sections for the hospital, and 
increases in the number of babies with macrosomia at 
birth and the number of pregnancies in older women.39
In our study, the percentages of neonates who were 
diagnosed with IUGR or SGA and mean birth weights 
were significantly higher in the SLE group than in the 
control group. Both of these terms (IUGR/SGA) are used 
as indicators of fetal growth restriction, but each involves 
a different mechanism. The definitions, we used for these 
terms, are provided in the methods section. Our findings 
are consistent with previous studies reporting growth 
restriction rates of 10%–28% in SLE groups.5 7 25 40 The 
risk of neonatal death is threefold higher in growth-re-
stricted neonates than in neonates with a normal 
weight.41 These infants also have high risk of developing 
other severe conditions, such as cardiovascular disease, 
infection and neurodevelopmental retardation.42 The 
risk of preterm birth was also threefold higher in both 
the very preterm or moderate to late preterm subgroups 
of women with SLE in our study, consistent with previous 
studies.4 5 7 24 36 40 43 Moreover, patients with SLE had a 
high risk of PPROM, but not PROM, which has not been 
reported in previous studies. The explanation for this 
finding might be that immune complexes cause vascular 
inflammation that contributes to a hypercoagulable state 
and subsequently reduces placental and umbilical artery 
blood flow and decreases placental perfusion and villus 
structure, thereby affecting fetal growth and prematu-
rity.18 44 Not surprisingly, the higher rates of prematurity 
and growth restriction observed in the SLE group led to a 
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higher NICU admission rate. However, differences in the 
Apgar scores of the neonates were not observed at either 
1 or 5 min, and the absolute incidence of moderate or 
severe hypoxia was very low in both group. This finding 
contrasts the result described in the study Wallenius et 
al,36 but this discrepancy may be because the size of the 
SLE group was small in the present study.
Four live births with congenital malformations occurred 
in the SLE group and 10 occurred in the control group, 
but the difference between the two groups was not signif-
icant. Among the four infants with congenital malfor-
mations in the SLE group, two had renal problems and 
one had polydactyly. Additionally, three cases of malfor-
mation in the SLE group were detected before 28 weeks 
and included one case of dextrocardia and two cases of 
maldevelopment of cardiac anatomy. These three cases 
were treated with a therapeutic abortion. Compared 
with previous studies, we reported a relatively low rate of 
congenital malformations in the present study. Wallenius 
et al
36 and Liu et al45 reported a rate of malformation of 
approximately 6%–7% in neonates born to women with 
SLE from approximately 2008–2009, and Rahman et al 
reported a rate of 2% from 1970 to 1995.46 One potential 
reason for these differences in the incidence of congen-
ital malformations is the extensive improvements in the 
prenatal diagnosis and antenatal management of these 
patients.
As medication is an important contributor to the preg-
nancy outcomes in women with SLE, we also collected 
the medication data in the present study. Steroids were 
the most common medication used by patients with SLE, 
but the exposure should be minimised during pregnancy. 
However, short-term administration of high doses should 
be used during a disease flare, and doses must be adminis-
tered at the time of delivery.3 Immunosuppressive therapy 
for SLE is often used to treat a flare. Azathioprine is the 
most commonly used drug during pregnancy, because it 
has proven safe for use during pregnancy.47 Antimalarial 
agents are now a first-line therapy for SLE during preg-
nancy. They are safe for pregnant women, and are proven 
to be associated with a reduced risk of congenital heart 
block in neonates.48 Aspirin has been proven to prevent 
pre-eclampsia in women with SLE.49 LMWH is safe and 
easy to administer, and along with low-dose aspirin, 
LMWH is routinely used in obstetric patients with APS.50
Strengths and limitations
The present study is noteworthy for several reasons. Preg-
nancy has been reported to be risky for women with SLE, 
due to the high rates of caesarean deliveries, infections, 
gestational hypertension and pre-eclampsia. However, this 
study is the first to compare maternal and fetal outcomes 
between pregnant women with and without SLE in a 
Chinese cohort. A nationwide population-based cohort 
was evaluated in Taiwan in 2010, but that study focused 
on only three fetal outcomes.25 Additionally, the present 
study included large samples of both patients with SLE 
and controls, comprising a total of 1350 individuals, and 
no data were missing for any of these patients. Further-
more, the maternal and fetal outcomes evaluated in this 
study were comprehensive and reflect almost every key 
aspect of pregnancy.
Nevertheless, our study has some limitations. First, 
as a retrospective study, this study has inherent biases, 
including selection bias and information bias. Second, the 
clinical records lacked some details regarding baseline 
population characteristics, including the level of educa-
tion, body mass index, daily activity and family income, 
of some of the included participants. These factors may 
be confounding factors in the present study. Finally, 
data for some variables, such as 24-hour urinary protein, 
complement, auto-antibody and aPL antibody levels, were 
not available for the non-SLE group because we do not 
perform these laboratory tests on patients without SLE 
manifestations. Therefore, we were unable to compare 
these variables between the two groups.
The generalisability of this study should be interpreted 
with caution due to this study conducted in a single 
tertiary university hospital in China.
CONCLUSIONS
In conclusion, the risks of gestational hypertension, 
pre-eclampsia, peripartum infection, PPROM and elective 
caesarean birth are higher and the risk of GDM is lower in 
pregnant women with SLE than in women without SLE. 
Additionally, SLE contributes to higher rates of fetal loss, 
prematurity, fetal growth restriction and NICU admis-
sion. We, therefore, suggest that women with SLE should 
have full access to preconception counselling, choose 
an optimal time for pregnancy and undergo close moni-
toring during antenatal care by both rheumatologists and 
obstetricians. Future large cohort studies should focus on 
antenatal management, including laboratory assessments 
and medication use, in pregnant women with SLE.
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